Efficacy and Safety of PD-1/PD-L1 Inhibitors Plus Chemotherapy Versus PD-1/PD-L1 Inhibitors in Advanced Non-Small Cell Lung Cancer: A Network Analysis of Randomized Controlled Trials

Immune checkpoint inhibitors (ICIs) are recommended as first-line treatment for late-stage non-small cell lung cancer (NSCLC), either as monotherapy or in combination with chemotherapy. However, efficacy and safety comparisons between ICIs as monotherapy and ICIs with chemotherapy are lacking. We se...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Xiang, Yan, Shi, Yang, Jichun, Wang, Yaqi, Lv, Chao, Li, Shaolei, Zhao, Jun, Yang, Yue, Zhuo, Minglei, Wu, Nan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7873939/
https://www.ncbi.nlm.nih.gov/pubmed/33585195
http://dx.doi.org/10.3389/fonc.2020.574752

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7873939/
https://www.ncbi.nlm.nih.gov/pubmed/33585195
http://dx.doi.org/10.3389/fonc.2020.574752

Ejemplares similares